Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction

Acute Cardiac Care

Volumn 10, Issue 1, 2008, Pages 49-57

  Christoph, Arnd ^a   Prondzinsky, Roland ^a   Russ, Martin ^a   Janusch, Matthias ^a   Schlitt, Axel ^a   Lemm, Henning ^a   Reith, Sebastian ^a   Werdan, Karl ^a   Buerke, Michael ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Acute myocardial infarction; IABP; Inotropic agents; Levosimendan; Myocardial infarction; Shock

Indexed keywords

DOBUTAMINE; HYPERTENSIVE AGENT; LEVOSIMENDAN; NORADRENALIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; BLEEDING; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; COUNTERPULSATION; FEMALE; HEART INDEX; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; HUMAN; INTRAAORTIC BALLOON COUNTERPULSATION; LIMB ISCHEMIA; MALE; MEAN ARTERIAL PRESSURE; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMIC VASCULAR RESISTANCE; VASCULAR ACCESS;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOTONIC AGENTS; FEMALE; HEMODYNAMICS; HUMANS; HYDRAZONES; INTRA-AORTIC BALLOON PUMPING; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; PULMONARY ARTERY; PYRIDAZINES; SHOCK, CARDIOGENIC; TIME FACTORS; VASCULAR RESISTANCE;

EID: 45849120152     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940701358564     Document Type: Article

References (29)

1. Hochman JS, Boland J, Sleeper LA, Porway M, Brinker J, Col J, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation. 1995;91:873-81.
2. Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med. 1999;341:625-34.
3. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
4. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-32.
5. Lehmann A, Lang J, Boldt J, Isgro F, Kiessling AH. Levosimendan in patients with cardiogenic shock undergoing surgical revascularization: a case series. Med Sci Monit. 2004;10:89-93.
6. De Luca L, Colucci W, Nieminen M, Massie BM, Gheorghiade M. Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006;27:1908-20.
7. Nieminen MS, Böhm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384-416.
8. De Luca L, Proietti P, Celotto A, Bucciarelli-Ducci C, Benedetti G, Di Roma A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J. 2005;150:563-8.
9. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2004;44:E1-E211.
10. Moulopoulos S, Stamatelopoulos S, Petrou P. Intraaortic balloon assistance in intractable cardiogenic shock. Eur Heart J. 1986;7:396-403.
11. Sanborn TA, Sleeper LA, Bates ER, Jacobs AK, Boland J, French JK, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36:1123-9.
12. Barron HV, Every NR, Parsons LS, Angeja B, Goldberg RJ, Gore JM, et al. Investigators in the National Registry of Myocardial Infarction 2. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J. 2001;141:933-9.
13. Stone GW, Ohman EM, Miller MF, Joseph DL, Christenson JT, Cohen M, et al. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003;41:1940-5.
14. Van de Werff F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28-66.
15. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340-8.
16. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med. 1999;131:47-59.
17. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998-3002.
18. Sleeper LA, Ramanathan K, Picard MH, Lejemtel TH, White HD, Dzarvik V, et al. Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2005;46:266.
19. Ohman EM, Hochman JS. Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit? Am Heart J. 2001;141:889-92.
20. Ohman EM, Nanas J, Stomel RJ, Leesar RJ, Nielsen DW, O'Dea D, et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis. 2005;19:33-9.
21. Stone GW, Marsalese D, Brodie BR, Griffin JJ, Donohue B, Costantini C, et al. A prospective, randomized evaluation of prophylactic intraaortic balloon counterpulsation in high risk patients with acute myocardial infarction treated with primary angioplasty. Second primary angioplasty in myocardial infarction (PAMI-II) trial investigators. J Am Coll Cardiol. 1997;29:1459-67.
22. Berger PB, Holmes DR Jr, Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. Circulation. 1997;96:122-7.
23. Santa-Cruz RA, Cohen MG, Ohman EM. Aortic counter-pulsation: a review of the hemodynamic effects and indications for use. Catheter Cardiovasc Interv. 2006;67:68-77.
24. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, et al. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail. 2003;5:443-51.
25. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31:638-44.
26. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J. 2005;26:1276-83.
27. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intracoronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg. 1997;85:23-9.
28. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol. 1999;34:219-28.
29. Garcia-González MJ, Domínguez-Rodríguez A, Ferrer-Hita JJ, Abreu-Gonzalez P, Munoz MB. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail. 2006;8:723-8.